Pharma - Multi Cap

Pharma - Multi Cap

by Axis Securities Ltd (ASL) Research


Multi-cap Pharma stocks,where we expect strong growth in the earnings given the lower base in the past & recovery in US business.

Investment Rationale

Overall Pharma sector was under pressure in the past 2 years. However, we believe progressive improvement in business outlook, primarily driven by healthy growth in domestic business, normalization of price erosion in US business coupled with big ticket launches for selected companies, and favorable currency movement.

About the Manager